格隆汇12月17日丨ST智知(603869.SH)公布，公司全资子公司新智认知数据服务有限公司（以下简称"数 据服务"）于2025年12月17日收到2024年度房产税退税款项，现将相关情况公告如下： 根据《国家税务总局上海市浦东新区税务局税务事项通知书》（沪浦税通〔2025〕25644号）、（沪浦 税税通〔2025〕466999号）（沪浦税通〔2025〕27560号）的批复，核准减免数据服务房产税，减征幅 度为100%，减征期间为2024年01月01日至2024年12月31日。数据服务于2025年12月17日收到2024年度 房产税退税款项342.39万元，占公司最近一个会计年度经审计归属于上市公司股东净利润的16.51%。 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 弘和仁愛醫療集團有限公司（於開曼群島註冊成立的有限公司) 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03869 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | 0.001 HKD | | | 500,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.001 HKD | | 500,000 | 本月底法定/ ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03869 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.001 HKD | | 500,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.001 HKD | | 500,000 | 本月底法定/註冊股本總額： HKD 500,000 第 1 頁 共 10 頁 v 1.1.1 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算 ...

Core Insights - ST Zhizhi (603869.SH) reported its Q3 2025 results on October 29, 2025, highlighting significant institutional investor interest in the company [1] Institutional Holdings - As of October 28, 2025, a total of 8 institutional investors disclosed their holdings in ST Zhizhi A-shares, with a combined shareholding of 324 million shares, representing 65.62% of the total share capital [1] - The institutional investors include notable entities such as Xin'ao Energy Supply Chain Co., Ltd., Tianjin Yienrui Investment Center (Limited Partnership), and others [1] - Compared to the previous quarter, the total institutional holding percentage increased by 1.35 percentage points [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 弘和仁愛醫療集團有限公司（於開曼群島註冊成立的有限公司) 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03869 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.001 HKD | | 500,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.001 HKD | | 500,000 | 本月底法定/註 ...

Financial Performance - For the six months ended June 30, 2025, the company reported revenue of RMB 743.0 million, a 3.3% increase from RMB 719.5 million in the same period last year[9]. - Adjusted gross profit for the same period was RMB 155.0 million, with an adjusted gross margin of 20.9%, down from 22.5% in the previous year[9][10]. - Adjusted net profit decreased to RMB 70.6 million, a decline of approximately 19.2% compared to RMB 87.3 million in the prior year[11]. - The company recorded a net profit of RMB 168.6 million, significantly up from RMB 23.6 million in the same period last year[10]. - The adjusted net profit margin for the first half of 2025 was 9.5%, down from 12.1% in the previous year[9]. - Adjusted operating profit was approximately RMB 102.5 million, down from RMB 123.0 million in the previous year, a decrease of about RMB 20.5 million attributed to reduced gross profit[16]. - The company reported a profit of RMB 168,620,000 for the six months ended June 30, 2025, compared to RMB 23,568,000 for the same period in 2024, representing a significant increase of 613%[93]. - Total comprehensive income for the period reached RMB 184,745,000, up from RMB 13,591,000 in the previous year, marking an increase of 1,262%[93]. Assets and Liabilities - As of June 30, 2025, total equity was approximately RMB 727.3 million, up from RMB 576.6 million as of December 31, 2024[17]. - Current assets were approximately RMB 1,019.7 million, a decrease of about RMB 79.4 million from RMB 1,099.1 million as of December 31, 2024, mainly due to a reduction in cash and cash equivalents[17]. - Current liabilities decreased significantly to approximately RMB 668.4 million from RMB 1,809.9 million as of December 31, 2024, primarily due to a reduction in convertible bonds[17]. - The company's cash and cash equivalents were approximately RMB 612.4 million as of June 30, 2025, down from RMB 714.1 million as of December 31, 2024[18]. - The total assets as of June 30, 2025, amounted to RMB 2,546,603 thousand, an increase from RMB 2,493,617 thousand as of June 30, 2024, showing a growth of about 2.1%[120][121]. - Total liabilities decreased to RMB 668,445,000 from RMB 1,809,925,000, a reduction of 63.0%[97]. - The net asset value increased to RMB 727,292,000 from RMB 576,623,000, representing an increase of 26.1%[97]. Shareholder Information - As of June 30, 2025, major shareholders hold significant stakes, with Hony Capital Fund V, L.P. owning 123,000,000 shares, representing approximately 89.01% of the company's issued shares[44]. - Hony Group Management Limited and its affiliates collectively hold 161,693,985 shares, accounting for about 117.01% of the company's issued shares[44]. - Liu Lu holds approximately 6.58% of the company's issued share capital through controlled entities[42]. - The company has a remaining share incentive plan authorization of 13,819,400 shares, equivalent to approximately 10% of the issued shares as of the report date[77]. Business Strategy and Operations - The company is focusing on enhancing its core competitiveness in the healthcare sector, particularly in the Yangtze River Delta region[11]. - The company is actively exploring innovative business models and increasing the application of new technologies such as artificial intelligence[11]. - The company aims to improve the quality of medical services while adapting to industry policy changes, including healthcare payment reforms[12]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[99]. Debt and Financing - The company has extended the maturity dates of convertible bonds with Yufeng Limited and Hony Capital Fund VIII to September 30, 2027, allowing for greater financial flexibility[13]. - The total principal amount of the convertible bonds issued to Hony Fund VIII is approximately HKD 773.9 million, with a similar extension of maturity to September 30, 2027[30]. - The company is focused on utilizing funds from the convertible bonds for future acquisitions and business expansion[46]. - The company has undergone several amendments to the terms of the convertible bonds, reflecting ongoing financial strategy adjustments[46]. Employee and Operational Costs - The total employee benefits expenditure for the six months ended June 30, 2025, was approximately RMB 244.0 million, compared to RMB 215.1 million for the same period in 2024[39]. - Employee costs for the six months ended June 30, 2025, were RMB 243,975 thousand, up from RMB 215,097 thousand in the same period last year, representing an increase of about 13.4%[125]. Regulatory and Compliance - The company is committed to regulatory compliance and standardized management practices in response to intensified market competition[12]. - The company has not used any derivative financial instruments to hedge foreign exchange risks and will consider appropriate hedging measures if necessary[34]. Dividends and Shareholder Returns - The company has decided not to declare any interim dividend for the six months ended June 30, 2025[38]. - The company did not recommend the payment of an interim dividend for the six months ended June 30, 2025, consistent with the previous year[150]. Accounting and Reporting - The company adopted a new accounting policy to use Hong Kong dollars as its functional currency starting January 1, 2025, due to its operations being primarily denominated in HKD[110]. - The review report confirms that no matters were found that would indicate the interim financial report as of June 30, 2025, was not prepared in accordance with International Accounting Standard 34[163].

致：香港交易及結算所有限公司 公司名稱: 弘和仁愛醫療集團有限公司（於開曼群島註冊成立的有限公司) 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03869 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.001 HKD | | 500,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.001 HKD | | 500,000 | FF301 本月底法定/註冊 ...

Core Viewpoint - 弘和仁爱医疗 (03869.HK) reported a revenue of RMB 743 million for the six months ending June 30, 2025, reflecting a year-on-year increase of 3.3% [1] Financial Performance - Revenue increased primarily due to a rise in comprehensive hospital service income from individual patients [1] - Gross profit amounted to RMB 147 million, showing a year-on-year decrease of 3.7% [1] - Net profit reached RMB 169 million, compared to RMB 23.568 million in the same period last year [1] - Basic earnings per share were RMB 1.13 [1]

Financial Performance - Revenue for the six months ended June 30, 2025, was RMB 743,044,000, an increase of 3.5% compared to RMB 719,503,000 for the same period in 2024[5] - Adjusted gross profit for the period was RMB 154,981,000, resulting in an adjusted gross margin of 20.9%, down from 22.5% in the previous year[5] - Adjusted net profit for the six months was RMB 70,584,000, with an adjusted net profit margin of 9.5%, compared to 12.1% in the prior year[5] - Basic earnings per share for the period was RMB 1.13, a significant recovery from a loss of RMB 0.15 per share in the same period last year[7] - Total comprehensive income for the period amounted to RMB 184,745,000, compared to RMB 13,591,000 in the same period last year[12] - The net profit for the six months ended June 30, 2024, was RMB 25,497 thousand, which was adjusted to RMB 23,568 thousand after accounting for changes[22] - The basic and diluted earnings per share for the six months ended June 30, 2024, were both reported at RMB (0.14), adjusted from RMB (0.15)[22] - The total comprehensive income for the period was RMB 21,270 thousand, which was adjusted to RMB 13,591 thousand after accounting for changes[22] - The segment profit before interest, tax, depreciation, and amortization (EBITDA) for the six months ended June 30, 2025, was RMB 135,018 thousand, compared to RMB 150,712 thousand in 2024, indicating a decrease of about 10.5%[28] - The net profit attributable to the company's owners for the six months ended June 30, 2025, was RMB 153,717 thousand, a significant recovery from a loss of RMB 20,647 thousand in the same period of 2024[36] Assets and Liabilities - Non-current assets as of June 30, 2025, totaled RMB 1,526,878,000, an increase from RMB 1,484,046,000 at the end of 2024[13] - Current liabilities decreased to RMB 668,445,000 from RMB 1,809,925,000 at the end of 2024, indicating improved liquidity[13] - As of June 30, 2025, the total non-current liabilities amounted to RMB 1,150,866 thousand, a significant increase from RMB 196,614 thousand in December 2024[14] - The net assets of the company reached RMB 727,292 thousand as of June 30, 2025, compared to RMB 576,623 thousand in December 2024, indicating a growth of approximately 26.1%[14] - The company's total equity increased to RMB 727,292 thousand as of June 30, 2025, up from RMB 576,623 thousand in December 2024, reflecting a growth of about 26.1%[14] - Total assets as of June 30, 2025, amounted to RMB 2,546,603 thousand, an increase from RMB 2,493,617 thousand as of June 30, 2024[28] - Total liabilities as of June 30, 2025, were RMB 1,819,311 thousand, compared to RMB 1,879,865 thousand as of June 30, 2024, reflecting a decrease of approximately 3.2%[28] - Trade receivables as of June 30, 2025, were RMB 143,674 thousand, up from RMB 131,263 thousand as of December 31, 2024, indicating an increase of about 9.5%[39] - Trade payables as of June 30, 2025, amounted to RMB 130.6 million, down from RMB 155.1 million as of December 31, 2024[9] Operational Strategy - The company plans to continue expanding its hospital management services and pharmaceutical sales to drive future growth[3] - The company is focusing on enhancing its operational efficiency and reducing costs to improve profit margins moving forward[3] - The company aims to innovate its business model in the second half of 2025, focusing on local policy guidance and expanding services such as health weight management clinics and family doctor services[48] - The company continues to enhance its core competitiveness in hospital management amidst increasing market competition and regulatory scrutiny[45] Employee and Administrative Expenses - The total employee count increased to 1,839 as of June 30, 2025, up from 1,491 a year earlier, primarily due to business expansion[71] - Employee benefit expenses totaled approximately RMB 244.0 million for the six months ended June 30, 2025, compared to RMB 215.1 million for the same period in 2024, reflecting a year-over-year increase[71] - Administrative expenses increased by approximately 25.7% to RMB 62.4 million, compared to RMB 49.6 million in the previous year, driven by business scale expansion[50] Financial Flexibility and Investments - The company successfully extended the maturity date of convertible bonds to September 30, 2027, allowing for greater financial flexibility and reduced cash outflow[47] - The company acquired 100% equity of Cixi Honghe Property Management Co., Ltd. for RMB 49.47 million, which will be consolidated into the group's financial statements[60] - The company has a revolving loan credit facility of RMB 150.0 million with an annual interest rate of 3.69%, effective until September 30, 2027[56] - The company believes it has sufficient working capital to meet operational needs based on available financial resources[54] Governance and Compliance - The company has adopted the corporate governance code as per Appendix C1 of the listing rules and believes it has complied with applicable provisions during the period[74] - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited performance and interim financial information, confirming compliance with applicable accounting standards and regulations[75] - The board is currently seeking a suitable candidate for the position of CEO to ensure compliance with the corporate governance code[74] - The chairman is also serving as the acting CEO until a new CEO is appointed, ensuring normal operations during this period[74] Foreign Exchange and Risk Management - The company faces foreign exchange risks primarily related to transactions in USD and HKD, with most transactions settled in RMB[66] Other Information - The company has not applied any new standards or interpretations that are not yet effective for the reporting period[19] - The company has not recorded any conversions of convertible bonds into ordinary shares during the reporting period[43] - The company decided not to declare any interim dividend for the six months ended June 30, 2025[70] - No significant events occurred after June 30, 2025, up to the date of this announcement[73] - There were no purchases, sales, or redemptions of the company's listed securities during the period, except as disclosed in the announcement[76] - The interim report will be published on the Hong Kong Stock Exchange and the company's website, and will be sent to shareholders at an appropriate time[77] - The announcement includes a note that certain figures have been rounded, which may result in discrepancies in totals[78]

Group 1 - ST Zhizhi (603869.SH) released its semi-annual report for 2025 on August 27, 2025 [1] - As of August 26, 2025, a total of 8 institutional investors disclosed holding ST Zhizhi A-shares, with a total holding of 324 million shares, accounting for 64.27% of ST Zhizhi's total share capital [1] - The institutional investors include New Energy Supply Chain Co., Ltd., Tianjin Yienrui Investment Center (Limited Partnership), Tianjin Xinyi Dehui Investment Management Center (Limited Partnership), New Energy Capital Management Co., Ltd., New Energy New Intelligence Technology Co., Ltd., New Energy Holdings Investment Co., Ltd., New Intelligence Cognitive Digital Technology Co., Ltd. - 2022 Employee Stock Ownership Plan, and Shenzhen Tianluo Information Consulting Co., Ltd. [1]